Johnson & Johnson (NYSE:JNJ) Stake Increased by First PREMIER Bank

First PREMIER Bank lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,651 shares of the company’s stock after buying an additional 278 shares during the quarter. Johnson & Johnson accounts for 2.0% of First PREMIER Bank’s portfolio, making the stock its 9th biggest holding. First PREMIER Bank’s holdings in Johnson & Johnson were worth $7,155,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Hibernia Wealth Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson in the third quarter worth $37,000. Tower View Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its holdings in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth $48,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Insider Transactions at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.4 %

NYSE:JNJ opened at $157.96 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The business’s 50-day simple moving average is $158.76 and its 200 day simple moving average is $156.69. The stock has a market cap of $380.65 billion, a price-to-earnings ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the prior year, the firm posted $2.35 earnings per share. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.